Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/43016
Full metadata record
DC FieldValueLanguage
dc.contributor.advisorWolfs, Esther-
dc.contributor.advisorLambrichts, Ivo-
dc.contributor.advisorVan Den Bosch, Ludo-
dc.contributor.authorLIBBERECHT, Karen-
dc.date.accessioned2024-05-29T09:28:24Z-
dc.date.available2024-05-29T09:28:24Z-
dc.date.issued2024-
dc.date.submitted2024-05-13T09:21:05Z-
dc.identifier.urihttp://hdl.handle.net/1942/43016-
dc.description.abstractThis work focuses on advancing fundamental research in CMT1A. Addressing the lack of available treatments for this disease, this thesis has three primary aims: developing novel human-based in vitro models, unraveling the underlying mechanisms of PMP22 gene overexpression in Schwann cells at a lysosomal level, and exploring the potential of rebalancing cAMP levels to alleviate the CMT1A phenotype (Fig. 1-4).-
dc.language.isoen-
dc.titleUnraveling CMT1A: Models, Mechanisms, and Therapeutic Approaches-
dc.typeTheses and Dissertations-
local.bibliographicCitation.jcatT1-
local.type.specifiedPhd thesis-
local.provider.typePdf-
local.uhasselt.internationalno-
item.fullcitationLIBBERECHT, Karen (2024) Unraveling CMT1A: Models, Mechanisms, and Therapeutic Approaches.-
item.embargoEndDate2029-05-29-
item.contributorLIBBERECHT, Karen-
item.fulltextWith Fulltext-
item.accessRightsEmbargoed Access-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Doctoraat FINAAL - Karen LIBBERECHT versie2 met cover.pdf
  Until 2029-05-29
Published version3.98 MBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.